The PI3K/AKT pathway plays an important role in the initiation and progression of cancer, and the drug development efforts targeting this pathway with therapeutic interventions have been advanced by academic and industrial groups. However, the clinical outcome is moderate. Combination of inhibition of PI3K/AKT and other targeted agents became a feasible approach. In this study we assessed the combined effect of ARQ 092, a pan-AKT inhibitor, and ARQ 087, a pan-FGFR inhibitor, in vitro and in vivo. In a panel of 45 cancer cell lines, on 24% (11 out of 45) the compounds showed synergistic effect, on 62% (28 out of 45) additive, and on 13% (6 out of 45) antagonistic. The highest percentage of synergism was found on endometrial and ovarian cancer cell lines. Mutational analysis revealed that PIK3CA/PIK3R1 mutations and aberrant activation of FGFR2 predicted synergism, whereas Ras mutations showed a reverse correlation. Pathway analysis revealed that a combination of ARQ 092 and ARQ 087 enhanced the inhibition of both the AKT and FGFR pathways in cell lines in which synergistic effects were found (AN3CA and IGROV-1). Cell cycle arrest and apoptotic response occurred only in AN3CA cell, and was not seen in IGROV-1 cells. Furthermore, enhanced antitumor activity was observed in mouse models with endometrial cancer cell line and patient-derived tumors when ARQ 092 and ARQ 087 were combined. These results from in-vitro and in-vivo studies provide a strong rationale in treating endometrial and other cancers with the activated PI3K/AKT and FGFR pathways. Anti-Cancer Drugs 28:503-513
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Introduction
PI3K/AKT is a major signaling pathway involved in various biological functions including cell cycle, proliferation/ growth, survival, metabolism, and metastasis, and it is one of the most frequently dysregulated pathways in cancer [1, 2] . It is evident that dysregulation, including hyperactivity, amplification, or activating mutations of genes encoding PI3K and AKT, or PTEN deficiency, can cause aberrant signaling of this pathway. Targeting the PI3K/ AKT pathway is a rational approach to fight cancer, and different PI3K/AKT inhibitors are in various stages of development [3] [4] [5] [6] .
In preclinical studies, PI3K and AKT inhibitors have shown significant single-agent efficacy both in vitro and in vivo [6] [7] [8] [9] [10] [11] . However, in the clinic, blockage of these targets has not produced the responses that the preclinical data set suggested [12, 13] . Unlike the resistance caused by acquired mutations on genes such as BCR-ABL and EGFR [14, 15] , compensatory signaling pathway changes appear to be the major event for the diminished efficacy of PI3K/AKT inhibitors. Inhibition of the PI3K/AKT pathway increased phosphorylation of MAPK through an S6-mediated negative feedback loop [16] . Chandarlapaty et al. [17] have shown that inhibition of AKT activity upregulated the expression and activity of many receptor kinases such as HER2 and HER3 through the feedback action of FOXO proteins [17] . Combination of PI3K/AKT/mTOR inhibitors with other targeted agents became an emerging approach to overcome such resistance [6, 10, [18] [19] [20] .
The efficacy of PI3K/AKT inhibitors is attenuated if alternative pathway(s) activated in parallel to the PI3K/ AKT pathway [21] [22] [23] . For instance, inhibition of the PI3K pathway did not induce significant apoptotic response in EGFR-addicted NSCLC cell lines, but combined inhibition of the PI3K and MAPK pathways achieved superior efficacy in vitro and in vivo [23] . Furthermore, in the cancer cell lines with genetically altered FGFR2, concomitant inhibition of FGFR and mTORC1 performed better in terms of antiproliferation and antitumor activity compared Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.anti-cancerdrugs.com).
with single agents [24, 25] . Clinical studies have been undertaken to evaluate the effect of PI3K/AKT pathway inhibitors in combination with estrogen antagonists, aromatase inhibitors, and HER2 inhibitors [26, 27] .
In this study, we assessed the combined effect of ARQ 092 and ARQ 087 in a panel of 45 cancer cell lines and showed that the highest synergism was found in endometrial and ovarian cancer cells. ARQ 092 is an oral, selective pan-AKT inhibitor that is potent against the AKTE17K activating mutation. ARQ 092 also demonstrates anticancer effect on cells bearing PIK3CA mutations [6] and is currently in phase I single-agent and combination clinical trials. ARQ 087 is a multikinase inhibitor with potent activity against FGFR1/2/3 [28] , being tested in a phase I/II trial for patients with intrahepatic cholangiocarcinoma. Cell cycle analysis using flow cytometry AN3CA and IGROV-1 cells were treated with ARQ 092 at 1 μmol/l or ARQ 087 at 1 μmol/l as single agents or combination for 72 h, trypsinized, washed in cold PBS, and stained using Cyletest Plus reagent kit (BD biosciences) according to the manufacturer's instruction. Cell cycle profile was analyzed using a FACS Calibur flow cytometer (BD Biosciences).
Western blot analysis
Cells treated under designated conditions were lysed using cell lysis buffer supplemented with Phosphatase and Protease Inhibitor cocktail (Sigma-Aldrich). For tumor tissue process, tumor samples were kept on dry ice at all times and a tissue pulverizer was dipped in liquid nitrogen before use. Tumor tissues were first pulverized and then lysed in cell lysis buffer supplemented with Halt Protease Phosphatase inhibitor (ThermoFisher, Waltham, Massachusetts, USA). Proteins were resolved in SDS-PAGE and transferred to PVDF membranes. After blockage with 5% BSA in TBX (1 × ) blocking buffer, the membranes were incubated with primary antibodies with 1% BSA in TBST overnight at 4°C and then blotted with HRP-conjugated secondary antibodies (Cell Signaling Technology). Immunoblotting detection was performed with GE ECL Prime reagent (GE Healthcare, Piscataway, New Jersey, USA) and images were captured using FuJi LAS 3000 system (FUJIFILM Corporation, Tokyo, Japan).
In-vivo studies
All experimental procedures were performed according to the Institutional Animal Care and Use Committee of Crown Biosciences Inc. (Santa Clara, California, USA) or START (San Antonio, Texas, USA).
AN3CA cells (5 × 10 6 ) were inoculated into female BALB/c nude mice. ARQ 092 was formulated in vehicle of 0.01 mol/l phosphoric acid pH22.25, and ARQ 087 was formulated in a vehicle of dimethylacetamide : cremophor EL : propylene glycol : 0.2 mol/l acetate buffer pH 5 (10 : 10 : 30 : 50). Tumor-bearing mice were dosed with ARQ 092 at 50, 75, or 100 mg/kg, or with ARQ 087 at 50 and 75 mg/kg or their combination orally once daily for 12 days. The efficacy of ARQ 092 and ARQ 087 in human endometrial PDX models was determined in START. Tumor-bearing mice were dosed with ARQ 092 at 100 mg/kg or ARQ 087 at 75 g/kg alone or in combination for 4 days followed by a 3-day break, for four cycles.
The tumor length and width (mm) were measured using a digital caliper. Estimated tumor volume (mm 3 ) was calculated according to the formula 1/2 × (tumor length) × (tumor width) 2 , shown as mean SEM. Percent inhibition or tumor growth inhibition (%TGI) was calculated using the formula: 1 − (mean tumor value of treated/mean tumor value of control) × 100.
Statistical analysis
All statistical analyses were performed using an unpaired t-test. Data were presented as mean SEM. A P value of less than 0.05 was considered to be statistically significant.
Pharmacokinetic analysis
Plasma and tumor samples were collected at 24 h after the last dose of ARQ 092, and plasma and tumor levels of ARQ 092 and ARQ 087 were determined by means of LC-MS/MS.
Results

Synergistic effect of ARQ 092 and ARQ 087 in endometrial and ovarian cancer cells in vitro
Inhibition of AKT by ARQ 092 has shown antiproliferative and antitumor effect [6] . Previous studies have shown that concurrent inhibition of the PI3K/AKT and FGFR pathways enhanced the antiproliferative effect in FGFR-addicted cells compared with single pathway inhibition [11, 24, 25, 30] . We tested the combination of ARQ 092 and ARQ 087 on a panel of 45 cancer cell lines originating from ovarian, endometrial, colorectal, bladder, breast, lung, central nervous system, head and neck, cervix, vulvar cancer, lymphoma, and leukemia. CI at 50% effectiveness was determined on the basis of the median-effect principle by Chou-Talalay [29] . Combined treatment of ARQ 092 and ARQ 087 resulted in a synergistic effect in 24% (11 out It has been shown that the PI3K/AKT and FGFR pathways are frequently aberrant in endometrial and ovarian cancers [31] [32] [33] [34] . To determine whether synergism of ARQ 087 and ARQ 092 can be predicted by genetic characteristics of treated cells, we analyzed the somatic mutational status of selected genes in the entire panel of cancer cell lines treated and assessed any potential correlation. As shown in Fig. 1a , 38% (11 out of 29) of cell lines with PIK3CA/PIK3R1 mutations showed synergistic effect when ARQ 092 and ARQ 087 were combined, whereas cell lines with wild-type PIK3CA/R1 showed no synergism (P = 0.004). It has been shown that the mutational status of Ras (KRas, HRas, and NRas) could be a negative factor for various targeted therapies [35] . We analyzed the Ras mutation status in all tested cell lines to determine whether it has any effect on the combinatorial treatment of ARQ 092 and ARQ 087. As shown in Fig. 1b and Supplementary [39] . Synergistic effect was also observed in AN3CA and IGROV-1 cells when ARQ 092 and AZD4547, a FGFR inhibitor, were combined (data not shown). Cells were treated with ARQ 092 or ARQ 087 at various concentrations as single agents or combination, and phospho proteins pAKT (S473), pPRAS40 (T246), pS6 (S235/S236), and p4EBP1 (T37/T46) were assessed using reverse phase protein array. As shown in Fig. 2a , ARQ 092 but not ARQ 087 inhibited phosphorylation of AKT, PRAS40, S6, and 4EBP1 in both AN3CA and IGROV-1 cells. In CaoV3 cells, only inhibition of phospho-S6 was observed upon treatment with ARQ 087. Combined treatment with ARQ 092 and ARQ 087 resulted in the enhanced inhibition of pAKT (S473), pS6 (S235/236), p4EBP1 (T37/T46), and pPRAS40 (T246) in both AN3CA and IGROV-1 cells (synergistic) but not in Caov3 cells (additive). Furthermore, to assess changes in pathway in AN3CA and IGROV-1 cells after treatment with ARQ 092 or ARQ 087 as single agents or combination, we performed western blot analysis. As shown in Fig. 2b , ARQ 092 inhibited AKT and its downstream targets, whereas ARQ 087 suppressed phosphorylation of FGFR and ERK but had no effect on the direct AKT targets pFOXO, pGSK-3β, and pBAD. IGROV-1 cells exhibited no detectable pBAD. Combination of ARQ 092 and ARQ 087 markedly inhibited phosphorylation for S6 phosphorylation in both AN3CA and IGROV-1 cells Combined effect of ARQ 092 and ARQ 087 on signaling pathway. (a) AN3CA, IGROV-1, and Caov3 cells were treated with various concentrations of ARQ 092 or ARQ 087 as single agents or combination for 2 h. pAKT (S473), pPRAS40 (T246), pS6 (S235/S236), and p4EBP1 (T37/T46) were assessed using RPMA. (b) AN3CA and IGROV-1 cells were treated with ARQ 092 or ARQ 087 at 0.1 or 1 μmol/l as single agents or combination for 2 h. pFGFR, pAKT (S473), pERK1/2 (T202/Y204), pFoxO1 (T24)/3a(T32), pGSK-3β (S9), pBAD (S136), pS6 (S235/S236), pS6 (S240/S244), and their total proteins were assessed using western blot analysis.
of S6 with combined treatment of ARQ 092 and ARQ 087 may drive synergism for two agents.
Combination of ARQ 092 and ARQ 087 induced cell cycle arrest and apoptosis Next, we assessed the effect of combination of ARQ 092 and ARQ 087 on cell cycle and apoptotic response. AN3CA and IGROV-1 cells were treated with ARQ 092 and ARQ 087 at 1 μmol/l as single agents or combination for 72 h. As shown in Fig. 3 , and Supplementary Fig. 1 (Supplemental digital content 1, http://links.lww.com/ACD/ A194) in AN3CA cells, combined treatment led to cell cycle arrest in G1 phase, concomitant with a decrease in the percentage of cells in S phase. Significant apoptotic response was observed in AN3CA cells as an increase in sub-G1 phase. Interestingly, no change in cell cycle and apoptosis were observed in IGROV-1 cells. In-vivo pharmacodynamics and pharmacokinetic studies of combination of ARQ 092 and ARQ 087
To further assess target inhibition, we performed western blot analysis and evaluated the changes in the AKT pathway and FGFR phosphorylation. pFGFR, pAKT, pERK, pPRAS40, and pS6 were analyzed in the tumor samples from the control group and the group treated with ARQ 092 and ARQ 087. As shown in Fig. 5a and Supplementary Fig. 2 (Supplemental digital content 1, http://links.lww.com/ACD/A194), ARQ 092 inhibited AKT phosphorylation and its downstream targets PRAS40 and S6 but elevated phopho ERK, whereas ARQ 087 suppressed FGFR phosphorylation. Combination of ARQ 092 and ARQ 087 enhanced the inhibition of AKT, ERK, PRAS40, and S6. These data suggest that combination of ARQ 092 and ARQ 087 exerted enhanced AKT and FGFR pathway inhibition in vivo.
ARQ 092 and ARQ 087 concentrations were determined for three treatment groups: the ARQ 087 75 mg/kg, 092 100 mg/kg, and ARQ 087/092 75/100 mg/kg combination groups. In each group both tumor and plasma were assessed by means of LC-MS/MS analysis (5b). In the animals treated with ARQ 087, the mean plasma concentration was 1.1 0.4 µmol/l, and in the combined dosing group the mean ARQ 087 concentration was 2.7 0.8 µmol/l. For ARQ 092, plasma concentrations were 0.6 0.2 µmol/l in the single agent group and 0.7 0.6 µmol/l in the combination group. In tumors, the mean ARQ 087 levels were 20 0.4 µmol/l (0.4 µmol/l SD) in the single-agent treatment group and 110 64 µmol/l in the combination group, whereas the mean ARQ 092 tumor concentrations were 25 10 and 37 27 µmol/l, respectively.
Discussion
AKT acts as a critical node connecting the PI3K and mTOR pathways and many AKT inhibitors are in various development stages in addition to the development of PI3K and mTOR inhibitors. To improve the efficacy or overcome the resistance, the combination of AKT inhibitors and other agents appears a valid strategy. In combination with MEK inhibitors, inhibition of AKT enhanced antiproliferation in vitro and antitumor activity in vivo [6, 10, 19, 40] . Concurrent inhibition of the AKT pathway with other pathway inhibitors (e.g. estrogen receptor, androgen receptor, and HER2) also showed more effectiveness in preclinical studies [41] [42] [43] , and clinical studies for such combination have been undertaken [12, 27] . ARQ 092 is a selective and potent allosteric AKT inhibitor currently under phase I/Ib clinical investigation [6] . As a multikinase inhibitor, ARQ 087 preferably suppresses FGFR family members and is in phase I/II trial in patients with FGFR genetic alterations [28] . In this study, we report that the combination therapy of ARQ 092 and ARQ 087 exhibited more effectiveness in antitumor activity in-vitro and in-vivo compared with the same experimental drugs administered as single agents. We assessed the combined effect of ARQ 092 and ARQ 087 in 45 cancer cell lines representing 13 different tumor types. Synergism was observed in 24% (11 out of 45), and endometrial and ovarian cancers showed the highest percentage of synergism of 44 and 38%, respectively. Mutational analysis showed that PIK3CA and PIK3R1 significantly increased chance of synergism (38%) for ARQ 092 and ARQ 087 compared with the cell lines with wild type (0%). Our findings also demonstrated that activating mutations of Ras (including KRas, HRas, and NRas) are a negative predictor for synergism in combination of ARQ 092 and ARQ 087.
Furthermore, in addition to mutations of PIK3CA/PIK3R1, the activated FGFR pathway through mutations or ligand engagement may be required for such synergism to occur. It has been shown that endometrial cancers contain a high frequency of FGFR mutations, which were accompanied with PIK3CA mutations in many cases [31, 34] . FGFR mutations are rare in ovarian cancers but the majority of ovarian cancers express FGFR [32] . However, activation of the FGFR pathway by its ligands promotes tumor progression and associates with resistance to therapeutic agents [37] [38] [39] . Knockdown of FGFR1 and 2 improved the response of ovarian cancer cells to cisplatin treatment in vitro and in vivo [39] . It is evident that concurrent inhibition of the FGFR and AKT/mTOR pathways resulted in more significant antitumor activity in models with activated AKT/mTOR and FGFR signaling [11, 24, 25] . Thus, our data support the notion that combined therapy with ARQ 092 and ARQ 087 could be a feasible approach in endometrial and ovarian cancers with PIK3CA/ PIK3R1 mutation and activated FGFR pathway. However, activating mutations of Ras may counteract such synergistic effect [35] .
To understand the molecular mechanism for the changes in pathways, we analyzed the changes in AKT and FGFR pathways in vitro and in vivo. Enhanced inhibition of AKT and FGFR pathways only occurred in the cell lines (AN3CA and IGROV-1 cells) that exhibited synergistic sensitivity to combined treatment with ARQ 092 and ARQ 087 but not with Caov3 cells that exhibited only additive sensitivity. AN3CA cells bear mutations of PIK3R1, PTEN, and FGFR2, whereas IGROV-1 contains PIK3CA mutations and express wild-type FGFRs. Interestingly, suppression of phosphorylation of ribosomal protein S6 was particularly more significant in combination groups compared with single-agent groups in in-vitro cell models. The observations were further confirmed by our in-vivo study. However, the combination of ARQ 092 and ARQ 087 did not result in enhanced reduction of phosphorylation of direct AKT downstream targets (FOXO, GSK, and BAD), suggesting that suppression of FGFR and AKT affects distinct pathways. Thus, it is reasonable to believe that S6 could be a converging point for the PI3K/AKT and FGFR pathways.
Further inhibition of S6 phosphorylation may be required for the synergistic effect of ARQ 092 and ARQ 087 combination. It is evident that MAPK-associated RSK activity contributed to S6 phosphorylation through two distinct mechanisms: (a) inhibition of TSC1/TSC2 complex, which subsequently elevated mTORC activity toward S6 kinase/S6, or (b) direct phosphorylation of S6 at serine 235/236 sites [44] [45] [46] . Other studies have also shown that, in FGFR-addicted cell lines, concomitant inhibition of mTOR and FGFR exerted more reduction in S6 phosphorylation compared with the single agents [24, 25] . In-vivo efficacy study in xenograft model with endometrial AN3CA cells showed that the combination of ARQ 092 at 50, 75, or 100 mg/kg with ARQ 087 at 50 and 75 mg/kg exerted significant TGI. At maximum tolerated doses of ARQ 092 (100 mg/kg) and ARQ 087 (75 mg/kg), the highest TGI (86%) resulted, but was associated with severe toxicity with a body weight loss of 21.4% in the end of study. The toxicity was minimized when mice were dosed with ARQ 092 at 50 mg/kg + ARQ 087 (TGI = 72%) at 75 mg/kg, and ARQ 092 at 75 mg/ kg + ARQ 087 at 50 mg/kg (TGI = 78%). Only 11.5 and 10.9% body weight loss was observed, respectively, in each group. Interestingly, plasma and tumor concentrations from this study revealed that, when dosed in combination with ARQ 092, ARQ 087 plasma and tissue levels are elevated by 2-5-fold. The precise reason for the higher ARQ 087 levels is incompletely understood, and may be due to alterations in the absorption and metabolism of the combined agents. In addition, this may be the cause for the increased toxicity observed in the animals dosed with both compounds; however it is notable that ARQ 087 concentrations as high as those observed in the combo group have been seen in previous xenograft studies without any increased toxicity [28] .
The toxicity data suggests that continuous dosing of both agents may be suboptimal. Subsequently, in a modified dosing regimen of ARQ 092 at 100 mg/kg and ARQ 087 at 75 mg/kg 4 days on and 3 days off per week, enhanced antitumor activity was observed in one of the two endometrial PDX with PIK3CA and FGFR mutations, with no toxicity observed. Therefore, our in-vivo efficacy data provide a basis for the combination of these two agents only if the ideal dosing regimen can be achieved. Finally, in 7-day toxicity studies in rats, ARQ 092 (15 mg/kg) and ARQ 087 (50 mg/kg) combinations were well tolerated, suggesting that the toxicity observed in the xenograft models may be driven by species-specific metabolism ( Supplementary Fig. 3 , Supplemental digital content 1, http://links.lww.com/ACD/A194).
ARQ 092 and ARQ 087 are being tested in clinical trials as single agents (NCT01473095, NCT01752920), with encouraging signs of efficacy in different cancer types. An increasingly common strategy in cancer treatment involves the combination of agents targeting different pathways or targeting the same pathway at multiple points [26, 27] , and as recently shown by Davies et al. [30] in endometrial and bladder tumors, there is a preclinical and clinical rationale for combining AKT and FGFR inhibitors.
In summary, we have demonstrated in this study that the combination of ARQ 092 and ARQ 087 exerted enhanced antiproliferative activity in vitro and antitumor activity in vivo. Mutations of PIK3CA/PIK3R1 and FGFR may predict patients who are most likely to respond to the therapy, whereas activating mutations of Ras may prevent responses to these agents. Thus, the results provide an avenue for combined therapy of ARQ 092 and ARQ 087 in endometrial and other cancer patients with defined molecular signatures.
